310. 先天異常症候群 Congenital anomalies syndrome Clinical trials / Disease details
臨床試験数 : 10 / 薬物数 : 18 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01434745 (ClinicalTrials.gov) | September 2011 | 7/9/2011 | SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation | Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiving Cholesterol Supplementation | Smith-Lemli-Opitz Syndrome | Drug: Simvastatin;Dietary Supplement: Lactose | Oregon Health and Science University | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | 1 Year | 89 Years | All | 1 | N/A | United States |
| 2 | NCT01110642 (ClinicalTrials.gov) | July 2011 | 22/4/2010 | Novel Treatment for Syndromic Ichthyoses | Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses | Syndromic Ichthyoses;CHILD Syndrome;Smith Lemli Opitz Syndrome;Conradi Syndrome | Drug: Lovastatin | Northwestern University | NULL | Withdrawn | 1 Year | N/A | Both | 0 | Phase 2 | United States |
| 3 | NCT01356420 (ClinicalTrials.gov) | January 2011 | 11/5/2011 | Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome | Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation | Smith-Lemli-Opitz Syndrome | Dietary Supplement: Cholesterol supplementation | Oregon Health and Science University | NULL | Terminated | N/A | 85 Years | All | 21 | N/A | United States |
| 4 | NCT01773278 (ClinicalTrials.gov) | December 2008 | 3/12/2012 | Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) | Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) | Smith-Lemli-Opitz Syndrome;Cone-Rod Dystrophy;Hearing Loss | Drug: Antioxidants;Drug: Cholesterol | University of Colorado, Denver | NULL | Recruiting | N/A | 65 Years | All | 100 | Phase 2 | United States |
| 5 | NCT00114634 (ClinicalTrials.gov) | June 2005 | 15/6/2005 | Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome | Short-Term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome | Smith-Lemli-Opitz Syndrome | Dietary Supplement: Egg yolk preparation with cholesterol;Dietary Supplement: Egg substitute, without cholesterol | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | 4 Years | 17 Years | All | 13 | Phase 2 | United States |
| 6 | NCT00272844 (ClinicalTrials.gov) | January 1998 | 4/1/2006 | Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome | Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome | Smith-Lemli-Opitz Syndrome | Drug: crystalline cholesterol oil-based suspension | Boston Children’s Hospital | NULL | Completed | N/A | N/A | All | 23 | Phase 1/Phase 2 | United States |